EUVIMEDEUVIMED entdecken
Editorial

Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective

Miranda Davies, Linda Härmark

Drug Safety · 2026-09 · 49 (9) · 1005-1008

DOI: 10.1007/s40264-026-01676-4 ↗

Kurz gefasst

Editorial in der Zeitschrift Drug Safety, online erschienen am 05.05.2026. Verfasst von Miranda Davies und 1 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety Research Unit, Southampton, UK. miranda.davies@dsru.org. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Drug Safety Research Unit, Southampton, UK. miranda.davies@dsru.org.
  • School of Medicine, Pharmacy, and Biomedical Science, University of Portsmouth, Portsmouth, UK. miranda.davies@dsru.org.
  • Drug Safety Research Unit, Southampton, UK.
  • School of Medicine, Pharmacy, and Biomedical Science, University of Portsmouth, Portsmouth, UK.

Zitieren

APA

Davies, M., & Härmark, L. (2026). Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective. Drug Safety, 49(9), 1005-1008. https://doi.org/10.1007/s40264-026-01676-4

Vancouver

Davies M, Härmark L. Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective. Drug Safety. 2026;49(9):1005-1008. doi:10.1007/s40264-026-01676-4

BibTeX
@article{Davies2026,
  author = {Davies, Miranda and Härmark, Linda},
  title = {Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective},
  journal = {Drug Safety},
  year = {2026},
  volume = {49},
  number = {9},
  pages = {1005--1008},
  doi = {10.1007/s40264-026-01676-4}
}
Kostenlos starten →